Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi (azilsartan).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.

Americas

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.

Americas

Brussels under scrutiny for IP policy as US flags risks to innovation

1 May 2026 The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.

More features

Five generations at work: How teams are bridging the gap

Kilpatrick adds tech patent litigator and China expert to Chicago office

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

Brussels under scrutiny for IP policy as US flags risks to innovation

Squire Patton Boggs promotes partner to head Europe IP&T practice

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

More on this story

Editor's picks

Editor's picks

More features